Page last updated: 2024-08-05 10:44:44
saturated fatty aldehyde
A fatty aldehyde in which there is no carbon-carbon unsaturation.
ChEBI ID: 133249
Members (9)
Member | Definition | Role |
---|---|---|
2-ethylhexanal | A saturated fatty aldehyde that is heptane in which one of the hydrogens at position 3 has been replaced by a formyl group. It is a metabolite of the plasticisers di-2-ethylhexyl phthalate (DEHP) and di-2-ethylhexyl adipate (DEHA). | 2-ethylhexanal |
caprylic aldehyde | A saturated fatty aldehyde formally arising from reduction of the carboxy group of caprylic acid (octanoic acid). | octanal |
decanaldehyde | A saturated fatty aldehyde formally arising from reduction of the carboxy group of capric acid (decanoic acid). | decanal |
heptanal | An n-alkanal resulting from the oxidation of the alcoholic hydroxy group of heptan-1-ol to the corresponding aldehyde. An endogenous aldehyde coming from membrane lipid oxidation, it is found in the blood of lung cancer patients and has been regarded as a potential biomarker of lung cancer. | heptanal |
n-hexanal | A saturated fatty aldehyde that is hexane in which one of the terminal methyl group has been mono-oxygenated to form the corresponding aldehyde. | hexanal |
nonanal | A saturated fatty aldehyde formally arising from reduction of the carboxy group of nonanoic acid. Metabolite observed in cancer metabolism. | nonanal |
pentanal | A saturated fatty aldehyde composed from five carbons in a straight chain. | pentanal |
pristanal | pristanal | |
undecanal | A saturated fatty aldehyde formally arising from reduction of the carboxylic acid group of undecanoic acid. It is a component of essential oils from citrus plants like Citrus reticulata. | undecanal |
Research
Studies (663)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 34 (5.13) | 18.7374 |
1990's | 68 (10.26) | 18.2507 |
2000's | 191 (28.81) | 29.6817 |
2010's | 261 (39.37) | 24.3611 |
2020's | 109 (16.44) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 2 (0.23%) | 5.53% |
Reviews | 7 (0.82%) | 6.00% |
Case Studies | 3 (0.35%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 845 (98.60%) | 84.16% |